To Evaluate Mucosal and Systematic Immune Response to Acute Respiratory Tract Infections of South African Children
Launched by DESMOND TUTU TB CENTRE · Mar 28, 2025
Trial Information
Current as of April 29, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is looking into how respiratory infections, like COVID-19, affect children in South Africa. Researchers want to understand how these infections show up in kids, which symptoms to look for, and which children are at higher risk of getting very sick. They will also study the immune response in kids—specifically, how immune cells in their saliva and blood react to these infections. Additionally, the study will assess how these respiratory infections impact children's lung function and their overall quality of life, as well as their families.
Children aged 0 to 13 years who are experiencing acute respiratory infections and visiting Tygerberg Hospital in Cape Town may be eligible to participate in this study. Participants will undergo tests to help researchers gather important information about their health and immune responses. This study aims to recruit at least 250 children, and by joining, families can contribute to understanding and improving care for respiratory infections in children.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • - Children aged 0-13 years with acute respiratory tract infections presenting to Tygerberg Hospital (TBH) in Cape Town, South Africa, for routine care
- Exclusion Criteria:
- • Admitted for \< 72 hours
About Desmond Tutu Tb Centre
The Desmond Tutu TB Centre, based at Stellenbosch University in South Africa, is a leading research organization dedicated to advancing the understanding and treatment of tuberculosis (TB). Founded in honor of Archbishop Desmond Tutu, the Centre focuses on innovative clinical trials and epidemiological studies to develop effective interventions against TB and improve patient outcomes. With a commitment to scientific excellence and community engagement, the Centre collaborates with local and international partners to address the global TB crisis and contribute to the eradication of this infectious disease.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Cape Town, Western Cape, South Africa
Cape Town, Western Cape, South Africa
Patients applied
Trial Officials
Marieke van der Zalm, PhD
Principal Investigator
Desmond Tutu TB Centre
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported